Guidance for Applicants

The Cure Parkinson’s Trust (CPT) funds and facilitates laboratory or clinical research projects with the potential to advance knowledge that might lead to a cure for Parkinson’s disease. 

We only accept research applications that meet the following criteria:

  • Disease modifying (slow, stop, reverse)
  • Translate into clinic (Phase 2b trial) within 5 years

We DO NOT accept symptomatic research or solely mechanistic or biomarker research.

Please read our full guidance for applicants to ensure that your project complies with our strict funding objectives before requesting a grant application form.

We are a member of the Association of Medical Research Charities (AMRC) which is recognised as a quality mark demonstrating that vigorous peer review** processes are in place ensuring that only the highest quality of research is supported. 

There are many legitimate areas of research into Parkinson’s that do not fall within the remit of CPT. We do, however, welcome enquiries from researchers who seek clarification on the suitability of projects CPT would consider for funding. 

** In 2015 alone we funded 21% of the projects submitted to us, or 53% of the projects which were sent for peer review - which meant the committee approved funding for £1,294,611 for research 

The Process

Applicants for grant funding are invited to submit their full proposal including budgets using the relevant forms (see the Applications Forms section below). Applications will be considered according to a number of criteria including their appropriateness to the central aim of The Cure Parkinson's Trust (CPT) i.e. their proximity to cure, originality, the potential clinical impact and achievability.

If the proposed project is considered appropriate to the charity’s objectives, it will first undergo a process of internal evaluation. The proposal is then sent for external peer review. At least two detailed external peer reviews are sought using CPT's external peer review protocol completed by our advisory panel and other acknowledged world experts in Parkinson’s research and treatment. If a compound is part of a proposal, an external commercial review may also be sought by trustees. Following external peer review, the proposed project application is then reviewed by the research committee (see below). The research committee prioritises and makes recommendations to the board of trustees which in turn make final funding decisions.

Application Forms

Before applying to CPT, or requesting an application form, please ensure that your project complies with our strict funding objectives (guidelines stated above). Applicants are invited to submit a full proposal, including budgets to Leah Mursaleen. Please email Leah for an application form or download and print this form.  If the project features a drug, please also complete the Drug CV Form.

Our research committee meets four times a year. Application deadlines for 2018 are set out below:  

- 1st February 
- 10th May 
- 16th August  
- 7th November  

Please also read our Terms and Conditions for Grant Funding.

** NOTE TO APPLICANTS - The Silverstein Foundation for Parkinson’s with GBA seeks to support research that will study and develop cell transplant therapies for Parkinson’s Disease. Specifically, the Silverstein Foundation is seeking proposal applications for cell transplant therapies with disease modifying potential and/or the potential to significantly improve symptomatic treatment beyond standard of care in GBA-related Parkinson’s Disease.

Areas of Interest - The Silverstein Foundation encourages proposals with a translational focus and a defined plan for moving toward clinical utility for patients. For more information click here.

                                                                                                                                                                    The Research Committee

Dr John Scadding OBE, Our research committee is chaired by Dr Scadding, Emeritus Dean of The Royal Society of Medicine and Honorary Consultant Neurologist to the National Hospital for Neurology and Neurosurgery, London.

Professor Tom Foltynie, Consultant Neurologist at The National Hospital for Neurology & Neurosurgery. Dr Foltynie is involved in trials of Duodopa, Exenatide and cell transplantation.

Dr Mike Hurley, senior researcher at Imperial College, London who has been a strong supporter and loyal advisor to the charity since it began.

Dr. Tilo Kunath, Senior Research Fellow and Group Leader at MRC Centre for Regenerative Medicine

Professor Andrew Lees, in 2011 Professor Lees was named the most highly cited Parkinson’s researcher. He is widely regarded as one of the most influential Parkinson’s experts in the world.

Dr Alan Whone, Consultant Senior Lecturer in Movement Disorders Neurology at the University of Bristol and Southmead Hospital, Bristol. 

Professor Alasdair Coles, Honorary Consultant Neurologist, Cambridge University Hospitals. Alasdair mainly treats people with multiple sclerosis also seeing people with general neurological problems and those with inflammatory diseases of the brain. 

Dr John Warren, is a clinical scientist who established Medicines Assessment Ltd as a pharmaceutical consultancy in 2011. He advises multiple pharmaceutical companies on clinical development.

Anthony Temple, is a recently retired QC and was a deputy High Court Judge.  For 12 years he chaired the Board of Pentathlon GB, the National Governing Body for the Olympic sport of Modern Pentathlon. Tony is particularly interested in the process and effectiveness of our project funding decisions and his aims include contributing well-informed views as a person with Parkinson’s to the Committee.       

Dr Richard Wyse, Dr Joy Duffen and Helen Matthews - The Cure Parkinson's Trust

Click here for more details of our research committee.